Denied
The Board found that the reduction in evaluation of prostate cancer residuals from 100 percent to 20 percent effective August 1, 2024, was proper.
The deciding factor: Improvement of prostate cancer has been demonstrated and will be maintained under ordinary conditions of life and work.
- Claimed conditions
- prostate cancer residuals
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- 20%
- Decision date
- November 4, 2025
- Citation
- A25095835
Want to see how appeals like this one tend to go? Appeals like mine
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.